BioSpace News Archive

Following Pre-NDA Meeting With FDA, Company Plans to Submit New Drug Application for Schizophrenia and Bipolar I Disorder Indications in the Fourth Quarter of 2019

Combination positions company to introduce next advance in multifocal contact lenses

Professor Jacky Smith from the University of Manchester to lead live webcast

AVROBIO, Inc. announced the first kidney biopsy result and additional positive data from two ongoing clinical trials of its AVR‑RD‑01 investigational gene therapy in Fabry disease.

Original metastatic castration-resistant prostate cancer and immunotherapy-refractory non-small cell lung cancer cohorts expanded to 80 subjects

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announces that The Lancet published online positive results from a Phase 3 pivotal clinical trial of rimegepant Zydis® orally dissolving tablet (ODT) for the acute treatment of migraine.

The Galien Foundation today announced the 2019 Annual Prix Galien USA Award nominees. Counted among the global health innovation industry’s most prized honors, the Prix Galien Award recognizes outstanding biomedical and medical technology product achievement that improves the human condition.

ESSA Pharma Inc. (“ESSA” or “the Company”) (NASDAQ: EPIX; TSX-V: EPI), a pharmaceutical company focused on the developing novel therapies for the treatment of prostate cancer, announced today the appointment of Dr. Alessandra Cesano, M.D., PhD as Chief Medical Officer (“CMO”).

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal third quarter ended June 30, 2019 after the U.S. markets close on August 6, 2019.

Apyx Medical Corporation, formerly Bovie Medical Corporation, (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, which is marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today announced the appointment of four members to its Medical Advisory Board.